BIVI
Biovie Inc
NASDAQ: BIVI · HEALTHCARE · BIOTECHNOLOGY
$1.46
+1.39% today
Updated 2026-10-28
Market cap
$11.90M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.05
Dividend yield
—
52W range
$1 – $4
Volume
2.6M
WallStSmart proprietary scores
25
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.5
Quality
B3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
-34.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →270 stocks currently score above 75
Price targets
Analyst target
$5.25
+259.59%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.03x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -34.39 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-4.12M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-50.26M | $-32.12M | $-17.54M | $-22.07M | $-5.65M |
| EPS | — | — | — | — | $-3.05 |
| Free cash flow | $-40.25M | $-27.95M | $-19.03M | $-19.02B | $-4.12M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Biovie Inc trades at $1.46. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -34.39, it sits in the distress.
Frequently asked questions
What is Biovie Inc's stock price?
Biovie Inc (BIVI) trades at $1.46.
Is Biovie Inc overvalued?
Biovie Inc carries a Smart Value Score of 25/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Biovie Inc (BIVI)?
The 12-month analyst consensus target is $5.25, about 259.6% above the current $1.46. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Biovie Inc's Altman Z-Score is -34.39, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-127.61%
Beta0.73
50D MA$1.64
200D MA$1.52
Shares out0.01B
Float0.01B
Short ratio—
Avg volume2.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—